March 17th, 2015
We all know a person with dementia or Alzheimer’s disease: a grandparent or friend, or we may have heard about someone famous who has been diagnosed. We have all heard stories from colleagues, or have our own experiences, with a family member who can no longer remember his children’s names, can no longer drive, and has trouble getting words out, and later on, needs help dressing. The gradual loss of cognition and ability to function slowly steals the person away and causes considerable suffering and hardship.
Approximately 44 million people worldwide suffer from dementia, and as the population ages, this number is expected to double by 2030 and more than triple by 2050. These are truly staggering projections, and the human aspects are heart-wrenching.
Johnson & Johnson and our Janssen pharmaceutical companies have never been more committed to helping people with dementia and Alzheimer’s disease. We recently announced an investment of $10 million through Johnson & Johnson Innovation – JJDC, Inc. in a new UK government-led dementia discovery fund that will support innovative research to prevent and treat these devastating conditions. We helped to create the fund as a new type of model to finance early, promising research, based on the reality that one company, one country, or one university cannot do it alone.